

Jason J Luke

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2961110/publications.pdf>

Version: 2024-02-01

235
papers

14,103
citations

61857

43
h-index

26548

107
g-index

246
all docs

246
docs citations

246
times ranked

21239
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluation of Dose Distribution to Organs-at-Risk in a Prospective Phase 1 Trial of Pembrolizumab and Multisite Stereotactic Body Radiation Therapy (SBRT). <i>Practical Radiation Oncology</i> , 2022, 12, 68-77.	1.1	5
2	Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas. <i>Clinical Cancer Research</i> , 2022, 28, 677-688.	3.2	119
3	A Pilot Study of Hepatic Irradiation with Yttrium-90 Microspheres Followed by Immunotherapy with Ipilimumab and Nivolumab for Metastatic Uveal Melanoma. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2022, 37, 11-16.	0.7	5
4	Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy. , 2022, 10, e004089.		50
5	Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 1939-1948.	0.8	29
6	Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or pascalisib in advanced solid tumors: a phase I study. , 2022, 10, e004223.		6
7	Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. <i>Lancet, The</i> , 2022, 399, 1718-1729.	6.3	236
8	Optimal systemic therapy for high-risk resectable melanoma. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 431-439.	12.5	12
9	Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 3990-4002.	3.2	15
10	The "Great Debate" at Melanoma Bridge 2021, December 2nd-4th, 2021. <i>Journal of Translational Medicine</i> , 2022, 20, 200.	1.8	0
11	Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment. <i>Journal of Clinical Oncology</i> , 2022, 40, 3741-3749.	0.8	33
12	Analysis of the effect of systemic corticosteroids on survival from tebentafusp in a phase 3 trial of metastatic uveal melanoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9584-9584.	0.8	1
13	Phase II study of nivolumab (nivo) with relatlimab (rela) in patients (pts) with first-line advanced melanoma: Early on-treatment major pathologic response on biopsy.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9514-9514.	0.8	1
14	Nivolumab (NIVO) + tacrolimus (TACRO) + prednisone (PRED) +/- ipilimumab (IPI) for kidney transplant recipients (KTR) with advanced cutaneous cancers.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9507-9507.	0.8	7
15	Phase 1 trial of TIM-3 inhibitor cobolimab monotherapy and in combination with PD-1 inhibitors nivolumab or dostarlimab (AMBER).. <i>Journal of Clinical Oncology</i> , 2022, 40, 2504-2504.	0.8	22
16	TAK-676 in combination with pembrolizumab after radiation therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), or squamous-cell carcinoma of the head and neck (SCCHN): Phase 1 study design.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS2698-TPS2698.	0.8	2
17	An open-label, multicenter, phase 1b/2 study of RP1, a first-in-class, enhanced potency oncolytic virus in solid organ transplant recipients with advanced cutaneous malignancies (ARTACUS).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS9597-TPS9597.	0.8	0
18	Model Informed Dosing Regimen and Phase I Results of the Anti-PD-1 Antibody Budigalimab (ABBV-181). <i>Clinical and Translational Science</i> , 2021, 14, 277-287.	1.5	5

#	ARTICLE	IF	CITATIONS
19	Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors. , 2021, 9, e002015.		23
20	Radiation treatment planning study to investigate feasibility of delivering Immunotherapy in Combination with Ablative Radiosurgery to Ultra-High DoSes (ICARUS). Journal of Applied Clinical Medical Physics, 2021, 22, 196-206.	0.8	2
21	High Throughput Multi-Omics Approaches for Clinical Trial Evaluation and Drug Discovery. Frontiers in Immunology, 2021, 12, 590742.	2.2	32
22	Case Report: Single Dose Anti-PD1 in a Patient With Metastatic Melanoma and Cardiac Allograft. Frontiers in Immunology, 2021, 12, 660795.	2.2	4
23	First-in-Human Phase I Study of ABBV-085, an Antibody-Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors. Clinical Cancer Research, 2021, 27, 3556-3566.	3.2	21
24	PSMA targeted armored chimeric antigen receptor (CAR) T-cells in patients with advanced mCRPC: A phase I experience.. Journal of Clinical Oncology, 2021, 39, 2534-2534.	0.8	6
25	Characterization of liver function tests (LFTs) following tebentafusp (tebe) in previously treated (2L+) metastatic uveal melanoma (mUM) patients (pts).. Journal of Clinical Oncology, 2021, 39, e21513-e21513.	0.8	1
26	Phase I dose escalation of KD033, a PDL1-IL15 bispecific molecule, in advanced solid tumors.. Journal of Clinical Oncology, 2021, 39, 2568-2568.	0.8	1
27	Characterization of cytokine release syndrome (CRS) following treatment with tebentafusp in patients (pts) with previously treated (2L+) metastatic uveal melanoma (mUM).. Journal of Clinical Oncology, 2021, 39, 9531-9531.	0.8	3
28	Phase I experience with first in class TnMUC1 targeted chimeric antigen receptor T-cells in patients with advanced TnMUC1 positive solid tumors.. Journal of Clinical Oncology, 2021, 39, e14513-e14513.	0.8	14
29	Multicenter phase I/II trial of encorafenib with and without binimetinib in combination with nivolumab and low-dose ipilimumab in metastatic BRAF-mutant melanoma.. Journal of Clinical Oncology, 2021, 39, TPS9596-TPS9596.	0.8	1
30	STING Agonists as Cancer Therapeutics. Cancers, 2021, 13, 2695.	1.7	181
31	A phase I dose-escalation study of intravenously (IV) administered TAK-676, a novel STING agonist, alone and in combination with pembrolizumab in patients (pts) with advanced or metastatic solid tumors.. Journal of Clinical Oncology, 2021, 39, TPS2670-TPS2670.	0.8	3
32	A phase 1/2, open-label, dose-escalation, safety and tolerability study of NC410 in subjects with advanced or metastatic solid tumors.. Journal of Clinical Oncology, 2021, 39, TPS2659-TPS2659.	0.8	0
33	Impact of the COVID-19 pandemic on staging at presentation of patients with invasive melanoma.. Journal of Clinical Oncology, 2021, 39, e21579-e21579.	0.8	2
34	Phase I study investigating the safety of stereotactic body radiotherapy (SBRT) with anti-PD-1 and anti-IL-8 for the treatment of multiple metastases in advanced solid tumors.. Journal of Clinical Oncology, 2021, 39, TPS2681-TPS2681.	0.8	2
35	Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy. Frontiers in Oncology, 2021, 11, 670726.	1.3	26
36	Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors. Clinical Cancer Research, 2021, 27, 5510-5518.	3.2	23

#	ARTICLE	IF	CITATIONS
37	Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastoma. , 2021, 9, e002417.		21
38	Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma. Cancer Discovery, 2021, 11, 2998-3007.	7.7	80
39	First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas. , 2021, 9, e002863.		20
40	Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma. Journal of Clinical Oncology, 2021, 39, 2647-2655.	0.8	94
41	Next-Generation Immunotherapy Approaches in Melanoma. Current Oncology Reports, 2021, 23, 116.	1.8	3
42	Punctate Anetoderma After Colony-Stimulating Factor 1 Receptor and Programmed Cell Death 1 Blockade With Irradiation. JAMA Dermatology, 2021, 157, 998.	2.0	2
43	Ipilimumab Combination Dosing: Less is More. Clinical Cancer Research, 2021, 27, 5153-5155.	3.2	6
44	Goals of Care and Patient-Centric Outcomes for Checkpoint Inhibitor Immunotherapy in Patients With Limited Performance Status. JCO Oncology Practice, 2021, , OP.21.00552.	1.4	1
45	Current strategies for intratumoural immunotherapy “ Beyond immune checkpoint inhibition. European Journal of Cancer, 2021, 157, 493-510.	1.3	28
46	1013P Similar overall survival in tebentafusp-treated 2L+ metastatic uveal melanoma regardless of prior immunotherapy. Annals of Oncology, 2021, 32, S854.	0.6	1
47	LBA3 Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: Efficacy and safety results from the KEYNOTE-716 double-blind phase III trial. Annals of Oncology, 2021, 32, S1314-S1315.	0.6	21
48	Transcriptional analysis of metastatic uveal melanoma survival nominates NRP1 as a therapeutic target. Melanoma Research, 2021, 31, 27-37.	0.6	6
49	Immune Checkpoint Inhibitors for Genitourinary Cancers: Treatment Indications, Investigational Approaches and Biomarkers. Cancers, 2021, 13, 5415.	1.7	13
50	950“...Final analysis: phase 1b study investigating intratumoral injection of toll-like receptor 9 agonist vidutolimod “ pembrolizumab in patients with PD-1 blockade“refractory melanoma. , 2021, 9, A999-A999.		6
51	Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis. Frontiers in Oncology, 2021, 11, 749064.	1.3	17
52	Randomized Phase II Trial and Tumor Mutational Spectrum Analysis from Cabozantinib versus Chemotherapy in Metastatic Uveal Melanoma (Alliance A091201). Clinical Cancer Research, 2020, 26, 804-811.	3.2	39
53	Considering adjuvant therapy for stage II melanoma. Cancer, 2020, 126, 1166-1174.	2.0	32
54	Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer. Cancer Discovery, 2020, 10, 40-53.	7.7	219

#	ARTICLE	IF	CITATIONS
55	KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma. <i>Future Oncology</i> , 2020, 16, 4429-4438.	1.1	59
56	Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial. <i>Clinical Cancer Research</i> , 2020, 26, 6437-6444.	3.2	43
57	Moving toward multi-dimensional biomarkers in cancer immunotherapy. <i>Chinese Clinical Oncology</i> , 2020, 9, 84-84.	0.4	0
58	ACE2 and Tmprss2 expression by clinical, HLA, immune, and microbial correlates across 34 human cancers and matched normal tissues: implications for SARS-CoV-2 COVID-19. , 2020, 8, e001020.		42
59	64MO A phase (ph) II, multi-center study of the safety and efficacy of tebentafusp (tebe) (IMCgp100) in patients (pts) with metastatic uveal melanoma (mUM). <i>Annals of Oncology</i> , 2020, 31, S1442-S1443.	0.6	21
60	Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets. <i>Nature Cancer</i> , 2020, 1, 1204-1217.	5.7	58
61	Toll-Like Receptor 9 Agonists in Cancer. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 10039-10061.	1.0	74
62	Molecular correlates and therapeutic targets in T cell-inflamed versus non-T cell-inflamed tumors across cancer types. <i>Genome Medicine</i> , 2020, 12, 90.	3.6	29
63	P01.01 A Phase Ia/Ib dose-escalation study of intravenously administered SB 11285 alone and in combination with nivolumab in patients with advanced solid tumors. , 2020, 8, A7.2-A8.		0
64	O85 Durable responses in anti-PD-1 refractory melanoma following intratumoral injection of a toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with pembrolizumab. , 2020, 8, A2.2-A3.		10
65	Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma. <i>Cancer Cell</i> , 2020, 38, 500-515.e3.	7.7	203
66	Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019). <i>TJ ETQq</i> 0.0 0 rgBT /Overlock	1.8	5
67	10200 A phase I, first-in-human, open-label, dose escalation study of MGD019, an investigational bispecific PD-1 x CTLA-4 DART® molecule in patients with advanced solid tumours. <i>Annals of Oncology</i> , 2020, 31, S704-S705.	0.6	3
68	598TiP A phase I/Ib dose-escalation study of intravenously administered SB 11285 alone and in combination with nivolumab in patients with advanced solid tumours. <i>Annals of Oncology</i> , 2020, 31, S500.	0.6	4
69	Safety and Efficacy of Multi-site Stereotactic Body Radiotherapy and Pembrolizumab for Patients with Large, Treatment-refractory Tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, S89-S90.	0.4	0
70	A case of dual-mechanism immune-related anaemia in a patient with metastatic melanoma treated with nivolumab and ipilimumab. , 2020, 8, e000380.		9
71	A Validated T Cell Radiomics Score Is Associated With Clinical Outcomes Following Multisite SBRT and Pembrolizumab. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 189-195.	0.4	15
72	PD-1 Blockade in Chinese versus Western Patients with Melanoma. <i>Clinical Cancer Research</i> , 2020, 26, 4171-4173.	3.2	13

#	ARTICLE	IF	CITATIONS
73	Response Criteria for Intratumoral Immunotherapy in Solid Tumors: itRECIST. <i>Journal of Clinical Oncology</i> , 2020, 38, 2667-2676.	0.8	44
74	Genomic Profiling of Metastatic Uveal Melanoma and Clinical Results of a Phase I Study of the Protein Kinase C Inhibitor AEB071. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1031-1039.	1.9	41
75	Tumor neoantigenicity assessment with CSiN score incorporates clonality and immunogenicity to predict immunotherapy outcomes. <i>Science Immunology</i> , 2020, 5, .	5.6	39
76	Biology confirmed but biomarkers elusive in melanoma immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 198-199.	12.5	4
77	Dendritic Cells, the T-cell-inflamed Tumor Microenvironment, and Immunotherapy Treatment Response. <i>Clinical Cancer Research</i> , 2020, 26, 3901-3907.	3.2	72
78	Inhibition of the Wnt/ β -catenin pathway enhances antitumor immunity in ovarian cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592091379.	1.4	21
79	Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule. <i>Cell Reports Medicine</i> , 2020, 1, 100163.	3.3	27
80	Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy. , 2020, 8, e001689.		33
81	304â€œ...Intratumoral injection of CMP-001, a toll-like receptor 9 (TLR9) agonist, in combination with pembrolizumab reversed programmed death receptor 1 (PD-1) blockade resistance in advanced melanoma. , 2020, , .		8
82	313â€œ...A phase 1 evaluation of tebotelimab, a bispecific PD-1 x LAG-3 DARTÂ® molecule, in combination with margetuximab in patients with advanced HER2+ neoplasms. , 2020, , .		7
83	Significant antitumor activity for low-dose ipilimumab (IPI) with pembrolizumab (PEMBRO) immediately following progression on PD1 Ab in melanoma (MEL) in a phase II trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10004-10004.	0.8	19
84	Initial report of treatment of uveal melanoma with hepatic metastases with yttrium90 internal radiation followed by ipilimumab and nivolumab.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10025-10025.	0.8	5
85	A phase I, first-in-human, open-label, dose-escalation study of MGD013, a bispecific DART molecule binding PD-1 and LAG-3, in patients with unresectable or metastatic neoplasms.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3004-3004.	0.8	30
86	A phase Ia/Ib dose-escalation study of intravenously administered SB 11285 alone and in combination with nivolumab in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS3162-TPS3162.	0.8	3
87	Improving therapy in metastatic uveal melanoma by understanding prior failures. <i>Oncoscience</i> , 2020, 7, 40-43.	0.9	0
88	Abstract B04: Molecular correlates of the non-T cell-inflamed tumor microenvironment in head and neck squamous cell carcinoma. , 2020, , .		0
89	Novel Immunotherapies and Novel Combinations of Immunotherapy for Metastatic Melanoma. , 2020, , 1165-1186.		0
90	489â€œ...The impact of education on novel concepts in adjuvant melanoma: a closer look at high risk stage II disease. , 2020, , .		0

#	ARTICLE	IF	CITATIONS
91	435â€¦A phase II trial of nivolumab plus axitinib in patients with anti-PD1 refractory advanced melanoma. , 2020, , .		0
92	367â€¦A phase 1/1b dose-escalation study of intravenously administered SB 11285 alone and in combination with atezolizumab in patients with advanced solid tumors. , 2020, , .		0
93	Platform Phase I Study Investigating the Safety of Multisite Stereotactic Body Radiotherapy with Immuno-Oncology Agents for the Treatment of Metastatic Advanced Solid Tumors. International Journal of Radiation Oncology Biology Physics, 2019, 104, 1193.	0.4	0
94	Combination of the indoleamine 2,3-dioxygenase 1 inhibitor (IDO1i) BMS-986205 with nivolumab (nivo): Updated safety across all tumors and efficacy in advanced bladder cancer (advBC) by patient (pt) subgroup. European Urology Supplements, 2019, 18, e1509-e1510.	0.1	1
95	Evaluation of a prototype treatment planning system (TPS) designed for biology-guided radiotherapy for SBRT of oligometastases. International Journal of Radiation Oncology Biology Physics, 2019, 104, 1196-1197.	0.4	0
96	A Validated Radiomics T Cell Score Predicts Response to Multi-site SBRT Combined with Pembrolizumab. International Journal of Radiation Oncology Biology Physics, 2019, 104, 1189-1190.	0.4	1
97	STING pathway agonism as a cancer therapeutic. Immunological Reviews, 2019, 290, 24-38.	2.8	204
98	Multi-Site SBRT and Sequential Pembrolizumab: Treated Metastasis Control and Immune-Related Expression Predict Outcomes. International Journal of Radiation Oncology Biology Physics, 2019, 104, 1190-1191.	0.4	5
99	Comprehensive Clinical Trial Data Summation for BRAF-MEK Inhibition and Checkpoint Immunotherapy in Metastatic Melanoma. Oncologist, 2019, 24, e1197-e1211.	1.9	15
100	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Oncology, The, 2019, 20, e378-e389.	5.1	155
101	Evaluation of Dose Distribution to Organs at Risk in a Prospective Study of Pembrolizumab and Multi-Site SBRT Using NRG-BR001 Constraints. International Journal of Radiation Oncology Biology Physics, 2019, 105, E766.	0.4	0
102	Phase I study evaluating safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ABBV-428, first-in-class mesothelin (MSLN)-CD40 bispecific, in patients (pts) with advanced solid tumours. Annals of Oncology, 2019, 30, v498-v499.	0.6	4
103	Secondary resistance to immunotherapy associated with β -catenin pathway activation or PTEN loss in metastatic melanoma. , 2019, 7, 295.		98
104	Tumor-reprogrammed resident T cells resist radiation to control tumors. Nature Communications, 2019, 10, 3959.	5.8	151
105	Feasibility of Delivering Immunotherapy with Concomittant Ablative Radiosurgery to Ultra-high DoSes (ICARUS). International Journal of Radiation Oncology Biology Physics, 2019, 105, E771.	0.4	1
106	A phase 2 study of glembatumumab vedotin, an antibodyâ€drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma. Cancer, 2019, 125, 1113-1123.	2.0	45
107	A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors. Oncology, 2019, 97, 102-111.	0.9	67
108	Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. , 2019, 7, 131.		64

#	ARTICLE	IF	CITATIONS
109	Approaches to High-Risk Resected Stage II and III Melanoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, e207-e211.	1.8	18
110	Response to Anti-PD-1 in Uveal Melanoma Without High-Volume Liver Metastasis. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 114-117.	2.3	48
111	Targeted agents or immuno-oncology therapies as first-line therapy for BRAF-mutated metastatic melanoma: a real-world study. Future Oncology, 2019, 15, 2933-2942.	1.1	32
112	The Gut Microbiome & Cancer Immunotherapy. Oncology Times, 2019, 41, 14-15.	0.1	1
113	BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma. Journal of Translational Medicine, 2019, 17, 386.	1.8	32
114	Facial Palsy Induced by Checkpoint Blockade: A Single Center Retrospective Study. Journal of Immunotherapy, 2019, 42, 94-96.	1.2	9
115	WNT/ β -catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers. Clinical Cancer Research, 2019, 25, 3074-3083.	3.2	435
116	The Impact of the Fecal Microbiome on Cancer Immunotherapy. BioDrugs, 2019, 33, 1-7.	2.2	10
117	Complete response of metastatic melanoma in a patient with Crohn's disease simultaneously receiving anti-IL27 and anti-PD1 antibodies. , 2019, 7, 1.		143
118	The T-cell-inflamed tumor microenvironment as a paradigm for immunotherapy drug development. Immunotherapy, 2019, 11, 155-159.	1.0	12
119	Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan-Kynurenine-Aryl Hydrocarbon Axis. Clinical Cancer Research, 2019, 25, 1462-1471.	3.2	271
120	Immunobiology, preliminary safety, and efficacy of CPI-006, an anti-CD73 antibody with immune modulating activity, in a phase 1 trial in advanced cancers.. Journal of Clinical Oncology, 2019, 37, 2505-2505.	0.8	27
121	Phase Ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced/metastatic solid tumors or lymphomas.. Journal of Clinical Oncology, 2019, 37, 2507-2507.	0.8	113
122	First-in-human phase 1 study of ABBV-085, an antibody-drug conjugate (ADC) targeting LRRC15, in sarcomas and other advanced solid tumors.. Journal of Clinical Oncology, 2019, 37, 3004-3004.	0.8	12
123	A phase I/Ib multicenter study to evaluate the humanized anti-CD73 antibody, CPI-006, as a single agent, in combination with CPI-444, and in combination with pembrolizumab in adult patients with advanced cancers.. Journal of Clinical Oncology, 2019, 37, TPS2646-TPS2646.	0.8	6
124	Phase I/Ib multicenter trial of TPST-1120, a peroxisome proliferator-activated receptor alpha (PPAR α) antagonist as a single agent (SA) or in combination in patients with advanced solid tumors.. Journal of Clinical Oncology, 2019, 37, TPS2665-TPS2665.	0.8	5
125	Pembrolizumab versus placebo as adjuvant therapy in resected high-risk stage II melanoma: Phase 3 KEYNOTE-716 study.. Journal of Clinical Oncology, 2019, 37, TPS9596-TPS9596.	0.8	5
126	BMS-986205, an indoleamine 2, 3-dioxygenase 1 inhibitor (IDO1i), in combination with nivolumab (nivo): Updated safety across all tumor cohorts and efficacy in advanced bladder cancer (advBC).. Journal of Clinical Oncology, 2019, 37, 358-358.	0.8	37

#	ARTICLE	IF	CITATIONS
127	Novel Immunotherapies and Novel Combinations of Immunotherapy. , 2019, , 1-22.		0
128	Phase III KEYNOTE-716 study: Adjuvant therapy with pembrolizumab versus placebo in resected high-risk stage II melanoma.. Journal of Clinical Oncology, 2019, 37, TPS145-TPS145.	0.8	1
129	Long-term clinical outcomes and transcriptional analysis following partial and complete tumor SBRT plus pembrolizumab.. Journal of Clinical Oncology, 2019, 37, 34-34.	0.8	0
130	Real-world time to next treatment (TTNT) for first-line (1L) targeted and immuno-oncology therapies for BRAF-mutated metastatic melanoma (MM) by lactate dehydrogenase (LDH) level.. Journal of Clinical Oncology, 2019, 37, 141-141.	0.8	1
131	PD47-01â€¦BMS-986205, AN INDOLEAMINE 2,3-DIOXYGENASE 1 INHIBITOR, PLUS NIVOLUMAB: UPDATED SAFETY ACROSS ALL TUMOR COHORTS AND EFFICACY IN ADVANCED BLADDER CANCER. Journal of Urology, 2019, 201, .	0.2	1
132	A phase I study evaluating COM701 in patients with advanced solid tumors.. Journal of Clinical Oncology, 2019, 37, TPS2657-TPS2657.	0.8	0
133	A phase I, first-in-human, open label, dose-escalation and cohort expansion study of MGD019, a bispecific DART protein binding PD-1 and CTLA-4 in patients with unresectable or metastatic neoplasms.. Journal of Clinical Oncology, 2019, 37, TPS2661-TPS2661.	0.8	2
134	Correlates of overall survival (OS) in metastatic uveal melanoma (mUM) and a randomized trial of cabozantinib (cabo) versus chemotherapy (chemo).. Journal of Clinical Oncology, 2019, 37, 9506-9506.	0.8	0
135	The newest treatments for uveal melanoma. Clinical Advances in Hematology and Oncology, 2019, 17, 490-493.	0.3	2
136	Further evidence to support judicious use of antibiotics in patients with cancer. Annals of Oncology, 2018, 29, 1349-1351.	0.6	6
137	Isolation and characterization of circulating melanoma cells by size filtration and fluorescent in-situ hybridization. Melanoma Research, 2018, 28, 89-95.	0.6	13
138	The commensal microbiome is associated with antiâ€œPD-1 efficacy in metastatic melanoma patients. Science, 2018, 359, 104-108.	6.0	2,027
139	Review of diagnostic, prognostic, and predictive biomarkers in melanoma. Clinical and Experimental Metastasis, 2018, 35, 487-493.	1.7	26
140	Firstâ€œinâ€œhuman trial of the PI3Kâ€œselective inhibitor SAR260301 in patients with advanced solid tumors. Cancer, 2018, 124, 315-324.	2.0	29
141	Safety and efficacy of the PD-1 inhibitor ABBV-181 in patients with advanced solid tumors: Preliminary phase I results from study M15-891. Annals of Oncology, 2018, 29, viii144.	0.6	3
142	Evaluation of a Prototype Treatment Planning System (TPS) for Biology-Guided Radiation Therapy (BgRT) in the Context of Stereotactic Body Radiation Therapy (SBRT) for Oligo-Metastases. International Journal of Radiation Oncology Biology Physics, 2018, 102, e514-e515.	0.4	2
143	Reply to S.C. Formenti et al. Journal of Clinical Oncology, 2018, 36, 2662-2663.	0.8	2
144	Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. Journal of Clinical Oncology, 2018, 36, 1611-1618.	0.8	448

#	ARTICLE	IF	CITATIONS
145	Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037). <i>Journal of Clinical Oncology</i> , 2018, 36, 3223-3230.	0.8	267
146	Anti-GITR agonist TRX518 in combination with gemcitabine in advanced solid cancers: Preliminary safety and efficacy from a multi-center phase Ib trial. <i>Annals of Oncology</i> , 2018, 29, x29.	0.6	0
147	NCMP-23. FACIAL PALSY INDUCED BY CANCER IMMUNOTHERAPY: A SINGLE CENTER RETROSPECTIVE STUDY. <i>Neuro-Oncology</i> , 2018, 20, vi198-vi198.	0.6	1
148	Safety of Immune Checkpoint Inhibitors for Cancer Therapy in IBD Patients. <i>American Journal of Gastroenterology</i> , 2018, 113, S406-S407.	0.2	0
149	Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma. <i>Melanoma Research</i> , 2018, 28, 605-610.	0.6	24
150	Characterization of the immune tumor microenvironment (TME) to inform personalized medicine with immuno-oncology (IO) combinations. <i>Annals of Oncology</i> , 2018, 29, viii403.	0.6	1
151	T Cell-Inflamed versus Non-T Cell-Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection. <i>Cancer Immunology Research</i> , 2018, 6, 990-1000.	1.6	297
152	The Evolution of Radiation Therapy in Metastatic Breast Cancer: From Local Therapy to Systemic Agent. <i>International Journal of Breast Cancer</i> , 2018, 2018, 1-7.	0.6	12
153	Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer. , 2018, 6, 24.		13
154	An Empirical Approach Leveraging Tumorgrafts to Dissect the Tumor Microenvironment in Renal Cell Carcinoma Identifies Missing Link to Prognostic Inflammatory Factors. <i>Cancer Discovery</i> , 2018, 8, 1142-1155.	7.7	138
155	Abstract 5737: Genomic drivers of cancer are enriched and mutually exclusive within non-T cell-inflamed tumors. , 2018, , .		1
156	Abstract CT144: Intratumoral toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with pembrolizumab can reverse resistance to PD-1 inhibition in a phase Ib trial in subjects with advanced melanoma. <i>Cancer Research</i> , 2018, 78, CT144-CT144.	0.4	43
157	A multicenter study of the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib plus durvalumab in patients with relapsed/refractory (R/R) solid tumors.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2578-2578.	0.8	19
158	BMS-986205, an indoleamine 2,3-dioxygenase 1 inhibitor (IDO1i), in combination with nivolumab (NIVO): Updated safety across all tumor cohorts and efficacy in pts with advanced bladder cancer (advBC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 4512-4512.	0.8	17
159	Safety and clinical activity of durvalumab in combination with tremelimumab in extensive disease small-cell lung cancer (ED-SCLC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 8517-8517.	0.8	19
160	Phase II trial of pembrolizumab (pembro) plus 1 mg/kg ipilimumab (ipi) immediately following progression on anti-PD-1 Ab in melanoma (mel).. <i>Journal of Clinical Oncology</i> , 2018, 36, 9514-9514.	0.8	19
161	Phase 1, open-label, adaptive biomarker trial that informs the evolution of combination immuno-oncology (IO) therapies (ADVISE), a precision IO approach to personalized medicine.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS3101-TPS3101.	0.8	3
162	A randomized phase II study of anti-PD1 antibody [MK-3475 (Pembrolizumab)] alone versus anti-PD1 antibody plus stereotactic body radiation therapy in advanced merkel cell carcinoma (Alliance) Tj ETQq0 0 0 rgBT / Overlock 10 Tf 50 57		

#	ARTICLE	IF	CITATIONS
163	Safety and clinical activity of pembrolizumab immunotherapy and multi-organ site ablative stereotactic body radiotherapy (iMOSART) in patients with advanced solid tumors.. Journal of Clinical Oncology, 2018, 36, 20-20.	0.8	1
164	Clinical and molecular features of innate and acquired resistance to anti-PD-1/PD-L1 therapy in lung cancer. Oncotarget, 2018, 9, 4375-4384.	0.8	26
165	Time to first-line (1L) therapy discontinuation in metastatic melanoma (MM).. Journal of Clinical Oncology, 2018, 36, 196-196.	0.8	0
166	Expansion cohort of partially irradiated tumors on a phase 1 trial of pembrolizumab and ablative radiotherapy.. Journal of Clinical Oncology, 2018, 36, TPS3122-TPS3122.	0.8	0
167	Objective response rate (ORR) and time to treatment failure (TTF) for BRAF v600 mutated metastatic melanoma (BRAF+ MM) patients receiving first-line (1L) targeted therapy (TT) or immuno-oncology (I-O) agents at US-based community oncology practices.. Journal of Clinical Oncology, 2018, 36, e21516-e21516.	0.8	0
168	Trial in progress: Platform phase 1 study investigating the safety of stereotactic body radiotherapy with immuno-oncology agents for the treatment of multiple metastases in advanced solid tumors.. Journal of Clinical Oncology, 2018, 36, TPS3121-TPS3121.	0.8	0
169	Objective response rate (ORR) and time to treatment failure (TTF) for BRAF v600 mutated metastatic melanoma (BRAF+ MM) patients receiving first-line (1L) treatment with dabrafenib/trametinib (D+T) v ipilimumab/nivolumab (I+N) and nivolumab or pembrolizumab (N/P) monotherapy at US-based community oncology practices.. Journal of Clinical Oncology, 2018, 36, e21538-e21538.	0.8	0
170	Diagnostic Comparison of CT Scans and Colonoscopy for Immune-Related Colitis in Ipilimumab-Treated Advanced Melanoma Patients. Cancer Immunology Research, 2017, 5, 286-291.	1.6	49
171	Clinical Features of Acquired Resistance to Anti-PD-1 Therapy in Advanced Melanoma. Cancer Immunology Research, 2017, 5, 357-362.	1.6	40
172	Patient perspectives on ipilimumab across the melanoma treatment trajectory. Supportive Care in Cancer, 2017, 25, 2155-2167.	1.0	14
173	Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nature Reviews Clinical Oncology, 2017, 14, 463-482.	12.5	945
174	Mechanistic and pharmacologic insights on immune checkpoint inhibitors. Pharmacological Research, 2017, 120, 1-9.	3.1	46
175	Cutting the Brakes: Immunotherapy With PD-1 Inhibitors. Clinical Skin Cancer, 2017, 2, 24-31.	0.1	2
176	Overcoming Chemoresistance with the Inhibition of the Wnt Pathway in Ovarian Cancer. Journal of the American College of Surgeons, 2017, 225, e131.	0.2	0
177	Abstract CT073: Immunomodulatory effects of nivolumab and ipilimumab in combination or nivolumab monotherapy in advanced melanoma patients: CheckMate 038. , 2017, , .		4
178	Abstract CT119: CPI-444, an oral adenosine A2a receptor (A2aR) antagonist, demonstrates clinical activity in patients with advanced solid tumors. Cancer Research, 2017, 77, CT119-CT119.	0.4	26
179	A phase II study of glembatumumab vedotin (GV), an antibody-drug conjugate (ADC) targeting gpNMB, in advanced melanoma.. Journal of Clinical Oncology, 2017, 35, 109-109.	0.8	8
180	Safety and clinical activity of adenosine A2a receptor (A2aR) antagonist, CPI-444, in anti-PD1/PDL1 treatment-refractory renal cell (RCC) and non-small cell lung cancer (NSCLC) patients.. Journal of Clinical Oncology, 2017, 35, 3004-3004.	0.8	37

#	ARTICLE	IF	CITATIONS
181	Identification of T-cell-inflamed gastric adenocarcinoma in The Cancer Genome Atlas (TCGA).. Journal of Clinical Oncology, 2017, 35, 16-16.	0.8	3
182	SBRT and the Treatment of Oligometastatic Disease. Cancer Treatment and Research, 2017, , 21-39.	0.2	0
183	Recent insights into the use of combination immunotherapy in solid tumors. Clinical Advances in Hematology and Oncology, 2017, 15, 588-591.	0.3	0
184	PS01.63: Clinical Characteristics of Acquired Resistance with Anti-PD-1/PD-L1 in Non-“Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology, 2016, 11, S310.	0.5	1
185	Optimal Use of BRAF Targeting Therapy in the Immunotherapy Era. Current Oncology Reports, 2016, 18, 67.	1.8	10
186	Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. , 2016, 4, 50.		413
187	The efficacy of anti-PD-1 agents in acral and mucosal melanoma. Cancer, 2016, 122, 3354-3362.	2.0	236
188	Clinical Response of a Patient to Anti-PD-1 Immunotherapy and the Immune Landscape of Testicular Germ Cell Tumors. Cancer Immunology Research, 2016, 4, 903-909.	1.6	45
189	Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E7759-E7768.	3.3	328
190	Single dose denileukin diftitox does not enhance vaccine-induced T cell responses or effectively deplete Tregs in advanced melanoma: immune monitoring and clinical results of a randomized phase II trial. , 2016, 4, 35.		21
191	Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. Journal of Clinical Oncology, 2016, 34, 3119-3125.	0.8	755
192	ASP9853, an inhibitor of inducible nitric oxide synthase dimerization, in combination with docetaxel: preclinical investigation and a Phase I study in advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2016, 77, 549-558.	1.1	15
193	Correlation of WNT/ β -catenin pathway activation with immune exclusion across most human cancers.. Journal of Clinical Oncology, 2016, 34, 3004-3004.	0.8	22
194	Safety and efficacy of durvalumab (MEDI4736), a PD-L1 antibody, in urothelial bladder cancer.. Journal of Clinical Oncology, 2016, 34, 4502-4502.	0.8	8
195	Clinical activity of anti-programmed death-1 (PD-1) agents in acral and mucosal melanoma.. Journal of Clinical Oncology, 2016, 34, 9516-9516.	0.8	1
196	A Phase II Randomized Study of CDX-1401, a Dendritic Cell Targeting NY-ESO-1 Vaccine, in Patients with Malignant Melanoma Pre-Treated with Recombinant CDX-301, a Recombinant Human Flt3 Ligand.. Journal of Clinical Oncology, 2016, 34, 9589-9589.	0.8	14
197	Biology of advanced uveal melanoma and next steps for clinical therapeutics. Pigment Cell and Melanoma Research, 2015, 28, 135-147.	1.5	81
198	Preliminary results from a Phase I/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers. , 2015, 3, .		66

#	ARTICLE	IF	CITATIONS
199	The genetic landscape of the T cell non-inflamed tumor microenvironment in human solid tumors. , 2015, 3, .		1
200	Systemic High-Dose Corticosteroid Treatment Does Not Improve the Outcome of Ipilimumab-Related Hypophysitis: A Retrospective Cohort Study. <i>Clinical Cancer Research</i> , 2015, 21, 749-755.	3.2	223
201	Single Institution Experience of Ipilimumab 3 mg/kg with Sargramostim (GM-CSF) in Metastatic Melanoma. <i>Cancer Immunology Research</i> , 2015, 3, 986-991.	1.6	21
202	Drug-Associated Dermatomyositis Following Ipilimumab Therapy. <i>JAMA Dermatology</i> , 2015, 151, 195.	2.0	144
203	Alliance A091103 a phase II study of the angiopoietin 1 and 2 peptibody trebananib for the treatment of angiosarcoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 629-638.	1.1	25
204	Antitumor Granuloma Formation by CD4 ⁺ T Cells in a Patient With Rapidly Progressive Melanoma Experiencing Spiking Fevers, Neuropathy, and Other Immune-Related Toxicity After Treatment With Ipilimumab. <i>Journal of Clinical Oncology</i> , 2015, 33, e32-e35.	0.8	21
205	A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue Sarcomas. <i>Oncologist</i> , 2015, 20, 1245-1246.	1.9	25
206	Targeted next-generation sequencing reveals high frequency of mutations in epigenetic regulators across treatment-naïve patient melanomas. <i>Clinical Epigenetics</i> , 2015, 7, 59.	1.8	49
207	First-in-human phase I trial of the PI3Kb-selective inhibitor SAR260301 in patients with advanced solid tumors (NCT01673737).. <i>Journal of Clinical Oncology</i> , 2015, 33, 2564-2564.	0.8	5
208	Density of immunogenic antigens and presence or absence of the T cell-inflamed tumor microenvironment in metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3002-3002.	0.8	10
209	PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma. <i>Oncotarget</i> , 2015, 6, 3479-3492.	0.8	146
210	Effect of denileukin diftitox (DD) on vaccine-induced T-cell responses and depletion of Tregs in melanoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3046-3046.	0.8	0
211	Abstract 1598: Isolation and characterization of circulating melanoma cells by size filtration and fluorescent in situ hybridization. , 2015, , .		0
212	New developments in the treatment of metastatic melanoma – role of dabrafenib–trametinib combination therapy. <i>Drug, Healthcare and Patient Safety</i> , 2014, 6, 77.	1.0	32
213	Ipilimumab administration for advanced melanoma in patients with pre-existing Hepatitis B or C infection: a multicenter, retrospective case series. , 2014, 2, 33.		52
214	The Biology and Clinical Development of MEK Inhibitors for Cancer. <i>Drugs</i> , 2014, 74, 2111-2128.	4.9	35
215	Noninvasive Detection of Response and Resistance in <i>EGFR</i> -Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA. <i>Clinical Cancer Research</i> , 2014, 20, 1698-1705.	3.2	717
216	Realizing the Potential of Plasma Genotyping in an Age of Genotype-Directed Therapies. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju214-dju214.	3.0	44

#	ARTICLE	IF	CITATIONS
217	Phase I study of the BRAF inhibitor dabrafenib (D) with or without the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutationâ€“positive unresectable or metastatic melanoma (MM).. Journal of Clinical Oncology, 2014, 32, 2511-2511.	0.8	41
218	Phase I dose-escalation study of the protein kinase C (PKC) inhibitor AEB071 in patients with metastatic uveal melanoma.. Journal of Clinical Oncology, 2014, 32, 9030-9030.	0.8	38
219	Landscape of genetic alterations in patients with metastatic uveal melanoma.. Journal of Clinical Oncology, 2014, 32, 9043-9043.	0.8	11
220	Kinase inhibitors and immune check-point blockade for the treatment of metastatic melanoma and advanced cancer: synergistic or antagonistic?. Expert Opinion on Pharmacotherapy, 2013, 14, 2457-2462.	0.9	12
221	Ipilimumab, Vemurafenib, Dabrafenib, and Trametinib: Synergistic Competitors in the Clinical Management of BRAF Mutant Malignant Melanoma. Oncologist, 2013, 18, 717-725.	1.9	72
222	Chemotherapy in the management of advanced cutaneous malignant melanoma. Clinics in Dermatology, 2013, 31, 290-297.	0.8	80
223	Imatinib for Melanomas Harboring Mutationally Activated or Amplified <i>KIT</i> Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin. Journal of Clinical Oncology, 2013, 31, 3182-3190.	0.8	530
224	Similar efficacy for phase I trials in comparison with DTIC for advanced malignant melanoma. Melanoma Research, 2013, 23, 152-158.	0.6	2
225	Clinical activity of ipilimumab for metastatic uveal melanoma. Cancer, 2013, 119, 3687-3695.	2.0	171
226	Ipilimumab for Patients With Advanced Mucosal Melanoma. Oncologist, 2013, 18, 726-732.	1.9	140
227	The Cyclin-Dependent Kinase Inhibitor Flavopiridol Potentiates Doxorubicin Efficacy in Advanced Sarcomas: Preclinical Investigations and Results of a Phase I Dose-Escalation Clinical Trial. Clinical Cancer Research, 2012, 18, 2638-2647.	3.2	85
228	Vemurafenib and BRAF Inhibition: A New Class of Treatment for Metastatic Melanoma. Clinical Cancer Research, 2012, 18, 9-14.	3.2	59
229	Advances in the Systemic Treatment of Cutaneous Sarcomas. Seminars in Oncology, 2012, 39, 173-183.	0.8	15
230	The Role of Comparative Effectiveness Research in Developing Clinical Guidelines and Reimbursement Policies. AMA Journal of Ethics, 2011, 13, 42-45.	0.4	3
231	Improving Quality and Addressing the Rising Costs of Cancer Care: Two Birds, One Stone. Journal of Oncology Practice, 2011, 7, 402-404.	2.5	2
232	Episode-Based Payment For Cancer Care: A Proposed Pilot For Medicare. Health Affairs, 2011, 30, 500-509.	2.5	51
233	Global Reimbursement: The Authors Reply. Health Affairs, 2011, 30, 1616-1616.	2.5	0
234	Lymphoma development in Bax transgenic mice is inhibited by Bcl-2 and associated with chromosomal instability. Cell Death and Differentiation, 2003, 10, 740-748.	5.0	30

#	ARTICLE	IF	CITATIONS
235	Neoantigen Clonal Balance Predicts Immunotherapy Outcomes and Prognosis. SSRN Electronic Journal, 0, , .	0.4	0